SULT2B1B sulfotransferase: Induction by vitamin D receptor and reduced expression in prostate cancer

Molecular Endocrinology

Volumn 27, Issue 6, 2013, Pages 925-939

  Seo, Young Kyo ^a   Mirkheshti, Nooshin ^a   Song, Chung S ^a   Kim, Soyoung ^a   Dodds, Sherry ^a   Ahn, Soon C ^a   Christy, Barbara ^a,c   Mendez Meza, Rosario ^a   Ittmann, Michael M ^b   Abboud Werner, Sherry ^a   Chatterjee, Bandana ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; SULFOTRANSFERASE; SULT2B1 PROTEIN; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR;

ANDROGEN SYNTHESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INDUCTION; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION;

ANIMALS; ANTIBODIES; ANTIBODY SPECIFICITY; BASE SEQUENCE; CALCITRIOL; CELL LINE, TUMOR; CELL PROLIFERATION; DNA FOOTPRINTING; ENZYME INDUCTION; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, INBRED C57BL; PROSTATE; PROSTATIC NEOPLASMS; PROTEIN BINDING; RECEPTORS, CALCITRIOL; RESPONSE ELEMENTS; SEQUENCE ANALYSIS, DNA; SULFOTRANSFERASES; TISSUE ARRAY ANALYSIS;

EID: 84877890627     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2012-1369     Document Type: Article

References (43)

1. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011; 364:1995-2005.
2. Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009;324:787-790.
3. Hofland J, van Weerden WM, Dits NF, et al. Evidence of Limited contributions for intratumoral steroidogenesis in prostate cancer. Cancer Res. 2010;70:1256-1264.
4. Chang KH, Li R, Papari-Zareei M, et al. Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. Proc Natl Acad Sci U S A. 2011;108:13728-13733.
5. Hofland J, van Weerden WM, Jenster G, Schröder FH, de Jong FH. Intraprostatic steroidogenic enzymes: response. Cancer Res. 2010; 70:8249-8250.
6. Mostaghel E, Nelson PS, Nelson C, and Montgomery RB. Intraprostatic steroidogenic enzymes: letter. Cancer Res. 2010;70: 8247-8249; author reply 8249-8250
7. Strott CA. Sulfonation and molecular action. Endocr Rev. 2002;23: 703-732.
8. Fuda H, Javitt NB, Mitamura K, Ikegawa S, Strott CA. Oxysterols are substrates for cholesterol sulfotransferase. J Lipid Res. 2007; 48:1343-1352.
9. Klein H, Bressel M, Kastendieck H, Voigt KD. Quantitative assessment of endogenous testicular and adrenal sex steroids and of steroid metabolizing enzymes in untreated human prostatic cancerous tissue. J Steroid Biochem. 1988;30:119-130.
10. He D, Falany CN. Inhibition of SULT2B1b expression alters effects of 3β-hydroxysteroids on cell proliferation and steroid hormone receptor expression in human LNCaP prostate cancer cells. Prostate. 2007;67:1318-1329.
11. Her C, Wood TC, Eichler EE, et al. Human hydroxysteroid sulfotransferase SULT2B1: two enzymes encoded by a single chromosome 19 Gene. Genomics. 1998;53:284-295.
12. Fuda H, Lee YC, Shimizu C, Javitt NB, Strott CA. Mutational analysis of human hydroxysteroid Sulfotransferase SULT2B1 isoforms reveals that exon 1B of the SULT2B1 gene produces cholesterol sulfotransferase, whereas exon 1A yields pregnenolone sulfotransferase. J Biol Chem. 2002;277:36161-36166.
13. Lee KA, Fuda H, Lee YC, Negishi M, Strott CA, Pedersen LC. Crystal structure of human cholesterol sulfotransferase (SULT2B1b) in the presence of pregnenolone and 3β-phosphoadenosine 5'-phosphate. J Biol Chem. 2003;278:44593-44599.
14. Sachdev D, Chirgwin JM. Fusions to maltose-binding protein: control of folding and solubility in protein purification. Methods Enzymol. 2000;326:312-321.
15. Chatterjee B, Echchgadda I, Song CS. Vitamin D receptor regulation of the steroid/bile acid sulfotransferase SULT2A1. Methods Enzymol. 2005;400:165-191.
16. Ayala G, Wang D, Wulf G, et al. The prolyl isomerase Pin1 is a novel prognostic marker in human prostate cancer. Cancer Res. 2003;63:6244-6251.
17. Weng VW, Ng L, Koh M, Tan SY, Tan PH. Is triple immunostaining with 34βE12, p63, and racemase in prostate cancer advantageous? A tissue microarray study. Am J Clin Pathol. 2007;127: 248-253.
18. Song CS, Kim JM, Roy AK, Chatterjee B. Structure and regulation of the senescence marker protein 2 gene promoter. Biochemistry. 1990;29:542-551.
19. Song CS, Echchgadda I, Seo YK, et al. An essential role of the CAAT/enhancer binding protein-alpha in the vitamin D-induced expression of the human steroid/bile acid-sulfotransferase (SULT2A1). Mol Endocrinol. 2006;20:795-808.
20. Shi L, Ko S, Kim S, et al. Loss of androgen receptor in aging and oxidative stress through Myb protooncoprotein regulated reciprocal dynamics of the tumor suppressor p53 and poly(ADP-ribose-)polymerase PARP-1. J Biol Chem. 2008;283:36474-36485.
21. Skowronski RJ, Peehl DM, Feldman D. Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology. 1993;132:1952-1960.
22. Blutt, SE, Allegretto EA, Pike JW, Weigel NL. 1,25-Dihydroxyvitamin D3 and 9-cis-retinoic acid act synergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cells in G1. Endocrinology. 1997;138:1491-1497.
23. Ting HJ, Messing J, Yasmin-Karim S, Lee YF. Identification of microRNA-98 as a therapeutic target inhibiting prostate cancer growth and a biomarker induced by vitamin D. J Biol Chem. 2013; 288:1-9.
24. Bender DA. Vitamin D. In: Nutritional Biochemistry of the Vitamins. 2nd ed. Cambridge, UK: Cambridge University Press; 2003: 77-108.
25. Hershberger PA, Yu WD, Modzelewski RA, Rueger RM, Johnson CS, Trump DL. Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis. Clin Cancer Res. 2001;7: 1043-1051.
26. Yu WD, Ma Y, Flynn G, et al. Calcitriol enhances gemcitabine anti-tumor activity in vitro and in vivo by promoting apoptosis in a human pancreatic carcinoma model system. Cell Cycle. 2010;9: 3022-3029.
27. Terpstra AH. Differences between humans and mice in efficacy of the body fat lowering effect of conjugated linoleic acid: role of metabolic rate. J Nutr. 2001;131:2067-2068.
28. Demetrius L. Of mice and men. When it comes to studying ageing and the means to slow it down, mice are not just small humans. EMBO Rep. 2005;6:S39-S44.
29. Titus MA, Schell MJ, Lih FB, Tomer KB, Mohler JL. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res. 2005;11:4653-4657.
30. Agoulnik IU, Vaid A, Bingman WE 3rd, et al. Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression. Cancer Res. 2005;65:7959-7967.
31. Agoulnik IU, Vaid A, Nakka M, et al. Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer. Cancer Res. 2006;66:10594-10602.
32. He D, Meloche CA, Dumas NA, Frost AR, Falany CN. Different subcellular localization of sulphotransferase 2B1b in human placenta and prostate. Biochem J. 2004;379:533-540.
33. Luo W, Karpf AR, Deeb KK, Muindi JR, Morrison CD, Johnson CS, Trump DL. Epigenetic regulation of vitaminD24-hydroxylase/ CYP24A1 in human prostate cancer. Cancer Res. 2010;70:5953-5962.
34. Ting HJ, Bao BY, Reeder JE, Messing EM, Lee YF. Increased expression of corepressors in aggressive androgen-independent prostate cancer cells results in loss of 1α,25-dihydroxy-vitamin D3 responsiveness. Mol Cancer Res. 2007;5:967-980.
35. Meyer MB, Watanuki M, Kim S, Shevde NK, Pike JW. The human TRPV6 distal promoter contains multiple vitamin D receptor binding sites that mediate activation by 1,25-dihydroxyvitamin D3 in intestinal cells. Mol Endocrinol. 2006;20:1447-1461.
36. Ramagopalan SV, Heger A, Berlanga AJ, et al. A ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution. Genome Res. 2010;20:1352-1360.
37. Lee YC, Higashi Y, Luu C, Shimizu C, Strott CA. Sp1 elements in SULT2B1b promoter and 5'-untranslated region of mRNA: Sp1/ Sp2 induction and augmentation by histone deacetylase inhibition. FEBS letters. 2005;579:3639-3645.
38. Mostaghel EA, Solomon KR, Pelton K, Freeman MR, Montgomery RB. Impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumors. PLoS One. 2012;7:e30062.
39. Lee JH, Gong H, Khadem S, et al. Androgen deprivation by activating the liver X receptor. Endocrinology. 2008;149:3778-3788.
40. Janowski BA, Willy PJ, Devi TR, Falck JR, Mangelsdorf DJ. An oxysterol signaling pathway mediated by the nuclear receptor LXR-α. Nature. 1996 383:728-731.
41. Chen W, Chen G, Head DL, Mangelsdorf DJ, Russell DW. Enzymatic reduction of oxysterols impairs LXR signaling in cultured cells and the livers of mice. Cell Metab. 2007;5:73-79.
42. Bai Q, Xu L, Kakiyama G, et al. Sulfation of 25-hydroxycholesterol by SULT2B1b decreases cellular lipids via the LXR/SREBP-1c signaling pathway in human aortic endothelial cells. Atherosclerosis. 2011;214:350-356.
43. Wagner D, Nonn L, Antonio A, et al. Double-blind randomized clinical trial of vitamin D3 showing effects on tissue calcitriol levels, gene expression and proliferation immunohistochemistry in prostate cancer. Cancer Res. 2012;72(8, Suppl 1)6 (Abstract LB-435).